NasdaqCM:POAI

Stock Analysis Report

Executive Summary

Predictive Oncology Inc. provides various healthcare products and services primarily in the United States.

Snowflake

Fundamentals

Mediocre balance sheet and overvalued.

Risks

  • Predictive Oncology has significant price volatility in the past 3 months.
  • Predictive Oncology is not covered by any analysts.

Similar Companies

Share Price & News

How has Predictive Oncology's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

1.8%

NasdaqCM:POAI

1.5%

US Medical Equipment

0.8%

US Market


1 Year Return

-47.1%

NasdaqCM:POAI

9.7%

US Medical Equipment

1.9%

US Market

POAI underperformed the Medical Equipment industry which returned 9.6% over the past year.

POAI underperformed the Market in United States of America which returned 2.1% over the past year.


Share holder returns

POAIIndustryMarket
7 Day1.8%1.5%0.8%
30 Day-10.3%0.7%3.4%
90 Day-1.9%2.4%2.1%
1 Year-47.1%-47.1%10.6%9.7%4.2%1.9%
3 Year-88.4%-88.4%70.2%65.0%46.7%37.2%
5 Year-99.7%-99.7%136.0%109.1%62.3%44.5%

Price Volatility Vs. Market

How volatile is Predictive Oncology's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Predictive Oncology undervalued based on future cash flows and its price relative to the stock market?

0.74x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Predictive Oncology to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Predictive Oncology to establish if it is available at substantial discount.


Price Based on Earnings

Predictive Oncology is loss making, we can't compare its value to the US Medical Equipment industry average.

Predictive Oncology is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Predictive Oncology, we can't assess if its growth is good value.


Price Based on Value of Assets

Predictive Oncology is good value based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Predictive Oncology expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.1%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Predictive Oncology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Predictive Oncology performed over the past 5 years?

-6.0%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Predictive Oncology does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Predictive Oncology's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Predictive Oncology's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Predictive Oncology has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Predictive Oncology has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Predictive Oncology improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Predictive Oncology's financial position?


Financial Position Analysis

Predictive Oncology's short term (1 year) commitments are greater than its holdings of cash and other short term assets.

Predictive Oncology's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Predictive Oncology's level of debt (17.1%) compared to net worth is satisfactory (less than 40%).

Predictive Oncology had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.


Balance Sheet

Low level of unsold assets.

Debt is not covered by short term assets, assets are 0.3x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Predictive Oncology has less than a year of cash runway based on current free cash flow.

Predictive Oncology has less than a year of cash runway if free cash flow continues to reduce at historical rates of -5.1% each year.


Next Steps

Dividend

What is Predictive Oncology's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Predictive Oncology's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Predictive Oncology's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Predictive Oncology has not reported any payouts.

Unable to verify if Predictive Oncology's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Predictive Oncology has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Predictive Oncology's salary, the management and board of directors tenure and is there insider trading?

2.1yrs

Average management tenure


CEO

Carl Schwartz (78yo)

2.8yrs

Tenure

US$242,636

Compensation

Dr. Carl I. Schwartz has been Chief Executive Officer of Precision Therapeutics Inc. (formerly known as Skyline Medical Inc.) since December 1, 2016. Dr. Schwartz served as the Interim Chief Executive Offi ...


CEO Compensation Analysis

Carl's remuneration is lower than average for companies of similar size in United States of America.

Carl's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

2.1yrs

Average Tenure

66yo

Average Age

The tenure for the Predictive Oncology management team is about average.


Board Age and Tenure

2.8yrs

Average Tenure

69.5yo

Average Age

The average tenure for the Predictive Oncology board of directors is less than 3 years, this suggests a new board.


Insider Trading

More shares have been bought than sold by Predictive Oncology individual insiders in the past 3 months, but not in substantial volumes.


Recent Insider Transactions

BuyUS$92006 Sep 19
Richard Gabriel
EntityIndividual
Role
Member of the Board of Directors
Director
Shares2,000
Max PriceUS$0.46
BuyUS$1,79426 Aug 19
Richard Gabriel
EntityIndividual
Role
Member of the Board of Directors
Director
Shares3,000
Max PriceUS$0.62
BuyUS$55,78828 May 19
Carl Schwartz
EntityIndividual
Role
Chief Executive Officer
CEO & Director
Shares100,000
Max PriceUS$0.56
BuyUS$50,00017 Jan 19
Carl Schwartz
EntityIndividual
Role
Chief Executive Officer
CEO & Director
Shares78,125
Max PriceUS$0.64
BuyUS$1,35812 Dec 18
Richard Gabriel
EntityIndividual
Role
Member of the Board of Directors
Director
Shares2,000
Max PriceUS$0.68
BuyUS$1,56029 Nov 18
Richard Gabriel
EntityIndividual
Role
Member of the Board of Directors
Director
Shares2,000
Max PriceUS$0.78
BuyUS$89023 Nov 18
Richard Gabriel
EntityIndividual
Role
Member of the Board of Directors
Director
Shares1,000
Max PriceUS$0.89

Ownership Breakdown


Management Team

  • Gerald Vardzel

    President of Helomics & Director

    • Tenure: 0.4yrs
  • Carl Schwartz (78yo)

    CEO & Director

    • Tenure: 2.8yrs
    • Compensation: US$242.64k
  • Dave Johnson (66yo)

    Senior Vice President of Operations - Skyline Medical Business Unit

    • Tenure: 1.1yrs
    • Compensation: US$215.07k
  • Bob Myers (64yo)

    CFO & Secretary

    • Tenure: 7.2yrs
    • Compensation: US$217.72k
  • Kevin Hungerford

    Vice President of Sales & Marketing

    • Tenure: 1.5yrs

Board Members

  • Mel Engle (69yo)

    Independent Director

    • Tenure: 2.9yrs
    • Compensation: US$29.70k
  • Paul Sweetnam

    Member of Scientific Advisory Board

    • Tenure: 3yrs
  • Richard Gabriel (70yo)

    Director

    • Tenure: 2.8yrs
    • Compensation: US$22.29k
  • Tom McGoldrick (78yo)

    Chairman

    • Tenure: 2.8yrs
    • Compensation: US$37.12k
  • Tim Krochuk (50yo)

    Independent Director

    • Tenure: 2.9yrs
    • Compensation: US$37.12k
  • Gerald Vardzel

    President of Helomics & Director

    • Tenure: 0.4yrs
  • Andrew Reding (49yo)

    Independent Director

    • Tenure: 13.7yrs
    • Compensation: US$22.29k
  • Carl Schwartz (78yo)

    CEO & Director

    • Tenure: 2.8yrs
    • Compensation: US$242.64k
  • Marc Malandro

    Member of Scientific Advisory Board

    • Tenure: 1yrs
  • Amelia Warner

    Member of Scientific Advisory Board

    • Tenure: 1yrs

Company Information

Predictive Oncology Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Predictive Oncology Inc.
  • Ticker: POAI
  • Exchange: NasdaqCM
  • Founded: 2002
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$16.552m
  • Shares outstanding: 31.26m
  • Website: https://www.precisiontherapeutics.com

Number of Employees


Location

  • Predictive Oncology Inc.
  • 2915 Commers Drive
  • Suite 900
  • Eagan
  • Minnesota
  • 55121
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
POAINasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDNov 2009
S1K1DB (Deutsche Boerse AG)YesCommon StockDEEURNov 2009

Biography

Predictive Oncology Inc. provides various healthcare products and services primarily in the United States. The company manufactures environmentally conscious systems for the collection and disposal of infe ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/18 00:40
End of Day Share Price2019/09/17 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.